BioSpace News Archive

Biomea Fusion, Inc. today announced the closing of its previously announced upsized underwritten public offering of 5,750,000 shares of its common stock.

Prime Therapeutics LLC is proud to announce that its companies, Magellan Rx Management, LLC and Magellan Pharmacy Solutions, Inc., have earned URAC re-accreditation for Pharmacy Benefit Management.

Avidity Biosciences, Inc. today announced that the company will host Volume 7 of its investor and analyst series focused on the topline safety, biomarker and functional data from the AOC 1001 Phase 1/2 MARINA™ trial in adults with myotonic dystrophy type 1 (DM1) on April 27, 2023 at 5:30 p.m. ET in Boston and available via webcast.

Alphatec Holdings, Inc. announced today that it will report first quarter financial results on May 4, 2023, after the market close.

Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced that the first participant has been dosed in the HELIOS study, a Phase 2 clinical trial of AMX0035 (sodium phenylbutyrate [PB] and taurursodiol [TURSO]) for the treatment of Wolfram syndrome (WS).

ZyVersa Therapeutics, Inc. announces publication of a review article in Frontiers in Pharmacology addressing the NLRP3 inflammasome pathway as a potential drug target for treating mild cognitive impairment (“MCI”) and AD.

Tivic Health® Systems, Inc. (“Tivic”) (Nasdaq: TIVC) today announced a research collaboration with The Feinstein Institutes for Medical Research to conduct a pilot clinical study that will test a novel non-invasive bioelectronic device approach for vagus nerve stimulation.

elo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the “Company” or “Telo”) is excited to announce that the abstract submitted to the American Society of Clinical Oncology (ASCO) 2023 annual meeting was accepted for presentation and will be published in the official proceedings of the meeting.

Pillar Biosciences, Inc. today announced a non-exclusive licensing agreement with Keygene N.V. related to their patent family entitled Combinatorial sequence barcodes for high throughput screening for use in Pillar Biosciences products, kits or services used for research or clinical testing.

NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damageNervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage,